Disc Medicine, Inc. (IRON) stock forecast & analysis
78.93
NasdaqGM · USDDelayed by 15 minutes
Up: +22.09, +38.9%
1 analysis
Latest analysis: · verdict locked
- Open
- 72.70
- Previous close
- 56.84
- Day range
- 69.98 – 80.22
- 52-week range
- 40.00 – 99.50
- Volume (shares)
- 8.48M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 38.39M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 2.11
- Market cap
- 3.03B
Market Scanner’s AI analysis of Disc Medicine, Inc. (IRON), updated October 2026: Disc Medicine's (IRON) stock surged on positive Phase 3 trial results for bitopertin, alongside a proposed securities offering.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Disc Medicine, Inc. (IRON) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Disc Medicine's (IRON) stock surged on positive Phase 3 trial results for bitopertin, alongside a proposed securities offering.
Recent analyses covered Disc Medicine's (IRON) significant stock price increase following the successful Phase 3 APOLLO trial results for bitopertin, a drug targeting erythropoietic protoporphyria (EPP). The trial met all primary and secondary endpoints, leading to hopes for FDA refiling and approval. The company also announced a proposed $350 million securities offering to fund further development. Market analysis noted the stock trading above its 50-day and 200-day SMAs, indicating a bullish trend, though the RSI neared overbought levels.
IRON news & sentiment
News reports highlighted significant positive sentiment following successful drug trial results, driving substantial stock price increases. Social media discussions reflected this optimism, with technical indicators showing strong buying pressure, though some noted the stock nearing overbought levels.
IRON technical picture
IRON traded above its 50-day and 200-day SMAs, indicating a bullish trend. Recent price momentum was strong, though RSI neared overbought levels and MACD suggested bearish momentum.
Fundamentals
The company has demonstrated a consistent year-over-year increase in operating and net losses. Total assets and liabilities have grown significantly, alongside substantial growth in shareholder equity.
Factors discussed — upside
- Successful Phase 3 APOLLO trial results for bitopertin met all primary and secondary endpoints.
- Stock trading above 50-day and 200-day SMAs indicating bullish trend.
- Strong recent upward momentum with a 7-day change of +30.5% and 30-day change of +13.5%.
- Money Flow Index (MFI) indicates positive buying pressure.
- Substantial growth in total assets and shareholder equity.
Factors discussed — risks
- Consistent increase in operating and net losses year-over-year.
- Relative Strength Index (RSI) nearing overbought threshold.
- MACD below zero suggesting bearish momentum.
- Clinical trial results
- Stock price momentum
- Financial performance
- Market technicals
Summary updated .
IRON technical indicators
Common technical indicators for IRON, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 71.54 | Price above |
| 10-day exponential moving average | 62.89 | Price above |
| Relative strength index (14-day) | 69.64 | Neutral |
| MACD line (12/26/9) | -2.2631 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 53.05 – 73.43 | Price above the upper band |
Analyses
Recent IRON.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-20 IRON.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Disc Medicine, Inc.?
- The bull case for Disc Medicine (IRON) centers on the successful Phase 3 APOLLO trial results for bitopertin, which met all primary and secondary endpoints, alongside substantial growth in assets and equity. The stock's technicals show a bullish trend with strong recent upward momentum and positive buying pressure.
- What are the risks for Disc Medicine, Inc.?
- Risks for Disc Medicine (IRON) include a consistent year-over-year increase in operating and net losses, and the stock's technical indicators showing the Relative Strength Index (RSI) nearing overbought levels and the MACD below zero suggesting bearish momentum.
- Is Disc Medicine, Inc. bullish or bearish?
- Recent AI analyses of Disc Medicine, Inc. examined factors on both sides. Discussed upside: The bull case for Disc Medicine (IRON) centers on the successful Phase 3 APOLLO trial results for bitopertin, which met all primary and secondary endpoints, alongside substantial growth in assets and equity. The stock's technicals show a bullish trend with strong recent upward momentum and positive buying pressure. Discussed risks: Risks for Disc Medicine (IRON) include a consistent year-over-year increase in operating and net losses, and the stock's technical indicators showing the Relative Strength Index (RSI) nearing overbought levels and the MACD below zero suggesting bearish momentum. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Disc Medicine, Inc.?
- News reports highlighted significant positive sentiment following successful drug trial results, driving substantial stock price increases. Social media discussions reflected this optimism, with technical indicators showing strong buying pressure, though some noted the stock nearing overbought levels.
- How does Market Scanner analyse Disc Medicine, Inc.?
- Every analysis of Disc Medicine, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Disc Medicine, Inc.?
The bull case for Disc Medicine (IRON) centers on the successful Phase 3 APOLLO trial results for bitopertin, which met all primary and secondary endpoints, alongside substantial growth in assets and equity. The stock's technicals show a bullish trend with strong recent upward momentum and positive buying pressure.
What are the risks for Disc Medicine, Inc.?
Risks for Disc Medicine (IRON) include a consistent year-over-year increase in operating and net losses, and the stock's technical indicators showing the Relative Strength Index (RSI) nearing overbought levels and the MACD below zero suggesting bearish momentum.
Is Disc Medicine, Inc. bullish or bearish?
Recent AI analyses of Disc Medicine, Inc. examined factors on both sides. Discussed upside: The bull case for Disc Medicine (IRON) centers on the successful Phase 3 APOLLO trial results for bitopertin, which met all primary and secondary endpoints, alongside substantial growth in assets and equity. The stock's technicals show a bullish trend with strong recent upward momentum and positive buying pressure. Discussed risks: Risks for Disc Medicine (IRON) include a consistent year-over-year increase in operating and net losses, and the stock's technical indicators showing the Relative Strength Index (RSI) nearing overbought levels and the MACD below zero suggesting bearish momentum. These are descriptive observations, not a recommendation.
What is the latest sentiment on Disc Medicine, Inc.?
News reports highlighted significant positive sentiment following successful drug trial results, driving substantial stock price increases. Social media discussions reflected this optimism, with technical indicators showing strong buying pressure, though some noted the stock nearing overbought levels.
How does Market Scanner analyse Disc Medicine, Inc.?
Every analysis of Disc Medicine, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh IRON.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.